Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial
Europace · 2025
DOI: 10.1093/europace/euaf175 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Wenzhi Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321, Zhongshan Roa…. Hauptthemen laut MEDLINE: Pulmonary Veins, Atrial Fibrillation, Vena Cava, Superior, Catheter Ablation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Affiliated Drum Tower Hospital, Medical School of Nanjing University, Beijing Xin Lian Zhi Cheng Cardiovascular Health Public Welfare Foundation.
Abstract (Originalsprache)
Aims
The superior vena cava (SVC) has been implicated as a non-pulmonary vein trigger in the initiation and maintenance of atrial fibrillation (AF). However, the incremental benefit of empiric SVC isolation (SVCI) in addition to pulmonary vein isolation (PVI) for paroxysmal AF (PAF) remains inconclusive. This study aimed to determine whether adding empiric SVCI to PVI improves freedom from atrial arrhythmia (ATA) recurrence in patients with PAF. Methods and results A total of 302 patients with PAF, aged 18–75 years, undergoing index ablation, were enrolled and randomized in a 1:1 ratio to either the PVI plus SVCI group or the PVI alone group between May 2021 and February 2024. In the PVI plus SVCI group, PVI was performed first, followed by empiric SVCI. In the PVI alone group, only PVI was performed. Among 302 randomized patients [median (IQR) age, 64.9 (56.0–70.0) years, 165 men (54.6%)], 302 (100%) completed the 3-month blanking period and contributed to the efficacy analysis. After a median follow-up of 20 months, the recurrence of rate of ATAs did not differ significantly between the PVI plus SVCI group (20/151 patients, 13.2%) and PVI alone group (29/151, 19.2%) without taking antiarrhythmic drugs (hazard ratio, 0.68, 95% confidence interval 0.38–1.20, P = 0.182). Subgroup outcomes analysis further demonstrated no significant interaction across subgroups.
Conclusion
Among patients with PAF undergoing initial ablation, the addition of empiric SVCI to PVI, compared with PVI alone, did not significantly improve freedom from ATA recurrence. Clinical trial registration This study was registered with Chinese Clinical Trials Registry: ChiCTR220005554.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321, Zhongshan Road, Nanjing 210008, China.
- Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Cardiovascular Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Cardiovascular Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Cardiovascular Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Cardiovascular Medicine, Yangzhou University Medical School Affiliated Shu Yang Hospital, Shuyang, China.
ORCID-Profile: Yuzhen Zhang, Weichun Qian, Chengzong Li, Wei Xu
Förderung
- Affiliated Drum Tower Hospital
- Medical School of Nanjing University
- Beijing Xin Lian Zhi Cheng Cardiovascular Health Public Welfare Foundation
Zitieren
APA
Shen, W., Zhang, Y., Qian, W., Li, C., Wang, C., Li, W., Li, J., Chen, J., Wei, Y., Liu, Y., Zhao, Y., & Xu, W. (2025). Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial. Europace. https://doi.org/10.1093/europace/euaf175
Vancouver
Shen W, Zhang Y, Qian W, Li C, Wang C, Li W, et al. Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial. Europace. 2025. doi:10.1093/europace/euaf175
BibTeX
@article{Shen2025,
author = {Shen, Wenzhi and Zhang, Yuzhen and Qian, Weichun and Li, Chengzong and Wang, Cheng and Li, Wei and Li, Jian and Chen, Juan and Wei, Youquan and Liu, Yu and Zhao, Yingming and Xu, Wei},
title = {Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf175}
}
EUVIMED